Table 3.
Top genes with myeloid leukemia or other immune-related functions
Gene | Type | Description |
---|---|---|
ZNF770 | Myeloid leukemia | This transcription factor’s binding motif is enriched in gene regulatory elements which are associated with AML relapse (Wiggers et al., 2019). |
RNF11 | Myeloid leukemia | This gene is differentially expressed between chronic phase CML and blast crisis CML (Jiang et al., 2013). |
C9orf47 | Myeloid leukemia | This gene is differentially expressed between NUP98-KDM5A+ pediatric AML and NUP98-KDM5A- pediatric AML (Noort et al., 2020). |
PRDM2 | Myeloid leukemia | PRDM2 expression is reduced in AML compared to normal bone marrow and is downregulated during CML progression (Lakshmikuttyamma et al., 2009; Sasaki et al., 2002). The repression of PRDM2 is involved in insulin-like growth factor-1 signaling activation in CML blast crisis cell lines (Pastural et al., 2007). |
C20orf197 | Other immune | This gene is differentially expressed between NUP98-KDM5A+ pediatric AML and NUP98-KDM5A- pediatric AML (Noort et al., 2020). |
CEBPD | Other immune | The encoded protein is important in the regulation of genes involved in immune and inflammatory responses, and may be involved in the regulation of genes associated with activation and/or differentiation of macrophages. |
SART3 | Other immune | The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. |
GPR35 | Other immune | This gene is expressed by monocytes and mast cells (Amir et al., 2018). |
Note: Genes are ranked by SCCA coefficient magnitude. Unless cited, descriptions are provided by NCBI.